High prevalence retina

OXU-001 (DME)

OXU-001 is being developed to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory for the treatment of DME, RVO and uveitis. Given this product profile, there is potential to expand OXU-001 development to radiation maculopathy and specifically to radiation-induced macular edema. OXU-001 are dexamethasone-containing Oxuspheres that are designed to be …

OXU-001 (DME) Read More »


OXU-005 is a potential first-in-class, long-lasting treatment for diabetic retinopathy. OXU-005 contains a proprietary narrow spectrum kinase inhibitor with potent anti-angiogenic and anti-inflammatory properties. OXU-005 will be prepared using long-lasting Oxuspheres and is designed to be delivered via Oxulumis to the posterior suprachoroidal space. Preclinical studies with OXU-005 demonstrate encouraging efficacy compared to benchmark clinical …

OXU-005 Read More »

Scroll to Top